Introduction
The abnormal activation of the phosphatidylinositol 3-kinase (PI3K)/Akt (Akt also known as protein kinase (PKB)) pathway ( Figure 1 ) has been validated by epidemiological and experimental studies as an essential step toward the initiation and maintenance of human tumors. Constitutive pathway activation can result from the distinct and/or complementary biological events including (i) constitutively active mutants or amplification of receptor tyrosine kinases (for example, epidermal growth factor receptor or ErbB2) leading to constitutive recruitment and activation of PI3K and downstream effectors; (ii) amplification of PI3K; (iii) presence of activating mutations in the PIK3CA gene encoding the p110a catalytic subunit; (iv) overexpression of the downstream kinase Akt; (v) loss or inactivating mutations of the tumor suppressor gene PTEN, an endogenous negative regulator of the PI3K pathway or (vi) constitutive recruitment and activation by mutant forms of the Ras oncogene (Carnero et al., 2008; Tokunaga et al., 2008; Maira et al., 2008b) . The preceding alterations trigger a cascade of biological events, from cell growth and proliferation to survival and migration, which drive tumor progression. In addition, for these cell autonomous survival and proliferation functions, PI3K is a key regulator of angiogenic pathways and upregulated metabolic activity in tumors. Finally, this pathway also plays a major part in the resistance of tumor cells to conventional cytotoxic and targeted anticancer therapies. Blocking the PI3K/Akt pathway could therefore simultaneously inhibit the proliferation and growth of tumor cells and sensitize them toward programmed cell death. To this end, drug discovery activities have been directed over the past few years to identify compounds that effectively and specifically disrupt this pathway in tumor cells. Here, the progress in the identification and development of compounds designed to target some of the intracellular components of the PI3K/Akt is reviewed.
Inhibitors of the lipid kinase activity of PI3K
The PI3Ks are widely expressed lipid kinases that phosphorylate phosphoinositides at the D-3 position of the inositol ring. These enzymes function as signal transducers downstream of cell-surface receptors. The products of PI3K-catalyzed reactions, phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P 3 ), phosphatidylinositol 3,4-bisphosphate (PtdIns(3,4)P 2 ) and phosphatidylinositol 3-phosphate (PtdIns(3)P), are second messengers and have central roles in a number of cellular processes, including cell growth, differentiation, mobility, proliferation and survival.
The eight members of the PI3K family have been classified into three groups based on their primary sequence, in vitro substrate preference, domain structure and mode of regulation. The subject of this section is class I PI3Ks, which is composed of two subgroups, IA and IB (Maira et al., 2008b) . The class IA PI3K subgroup consists of three catalytic subunits, p110a, p110b and p110d, that form heterodimers with one of five regulatory domains: p85a, p85b, p85g, p50a and p55a. As shown in Figure 1 , these PI3Ks are activated by cell-surface receptor tyrosine kinases. The class IB PI3K consists of one member, a heterodimer of p110g and a regulatory p101 domain, which is activated by G-proteins bg subunits following the stimulation of G-protein-coupled receptors. PI3Ks IA and IB catalyze the formation of PtdIns(3,4,5)P 3 , a process that is reversed by the action of the lipid phosphatase, PTEN.
Two well-known and isoform-unselective PI3K inhibitors are the fungal metabolite wortmannin (compound 1, Figure 2 ; Brian et al., 1957) and LY294002 (compound 2, Figure 2 ; Vlahos et al., 1994) . These compounds block the enzymatic activity of PI3Ks by different mechanisms. Thus, wortmannin is an irreversible inhibitor (IC 50 E2 nM) that forms a covalent bond with a conserved lysine residue involved in the phosphate-binding reaction (Wymann et al., 1996) , whereas LY294002 is a classical reversible, ATPcompetitive PI3K modulator (IC 50 ¼ 1.40 mM) (Vlahos et al., 1994; Davies et al., 2000) . In spite of the crossover inhibition of other lipid and PKs and their unfavorable pharmaceutical properties, wortmannin and LY294002 have served as important research tools for more than a decade in elucidating the role of PI3Ks in the biology of human cancers. In parallel with their preclinical use, the scaffolds of wortmannin and LY294002 have been the subjects of intense lead optimization efforts directed at improving upon the pharmaceutical limitations of the parent compounds. Thus, using wortmannin as a starting point, broad-spectrum PI3K inhibitors with improved pharmaceutical properties and therapeutic indexes such as PWT-458 (compound 3, Figure 2 ; Yu et al., 2005) and PX-866 (compound 4, Figure 2 ; Ihle et al., 2005; Howes et al., 2007) have been reported. PWT-458 is a PEGylated derivative of wortmannin that has a higher therapeutic index in preclinical animal models compared to the parent compound. Upon intravenous (i.v.) administration, the polyethylene-glycol (PEG) moiety is cleaved and 17-hydroxywortmannin is released. In vivo antitumor activity has been reported in several human xenograft models (for example, U87MG, A549 and A498). PX-866 is a semisynthetic viridin derivative that potently and irreversibly inhibits PI3Ka, g and d (IC 50 ¼ 5.5, 9.0 and 2.7 nM, respectively). Unlike wortmannin, it shows a certain level of selectivity over PI3Kb (IC 50 >300 nM) and higher stability. PX-866 suppresses the growth of several human tumor multicellular spheroids (for example, U87, PC3, T47D and HCT116) and provokes a more prolonged inhibition of PI3K than does wortmannin, The compound has antitumor activity against several human solid tumor models (for example, OvCar-3, HT-29 or A-549) when used alone (2 mg/kg, orally) or in combination with chemotherapeutic or targeted anticancer agents (for example, paclitaxel or gefitinib). In addition to a decrease in body weight and leukocytosis, a major toxicity of PX-866 administration to severe combined immunodeficient mice was hyperglycemia Figure 1 Schematic representation of the PI3K/Akt pathway and its main components. Upon activation by their cognate growth factors, PI3K recruitment to receptor tyrosine kinases leads to a transient increase in PIP3 levels. This phospholipid serves as an anchor point to recruit PH-domain containing proteins such as Akt. After translocation to the plasma membrane, Akt is phosphorylated on two distinct residues, Thr-308 and Ser-473, by PDK1 and PDK2 (mTORC2), respectively. Once fully activated, Akt phosphorylates and activates down stream cytosolic and nuclear effectors. In tumor cells, Akt is constitutively activated leading to dysregulated proliferation, cell growth and survival. Activation of this pathway is also involved in tumor angiogenesis, which results in the formation of a network of blood vessels that penetrates into the tumor tissue, supplying nutrients and oxygen and removing waste products. PDK1, phosphoinositide-dependent protein kinase-1; PH, plecstrin homology domain; PI3K, phosphatidylinositol 3-kinase.
Drug discovery approaches targeting the PI3K pathway C Garcia-Echeverria and WR Sellers Drug discovery approaches targeting the PI3K pathway C Garcia-Echeverria and WR Sellers with decreased glucose tolerance. These changes were dose-dependent and reversible upon discontinuation of the drug. These wortmannin derivatives have not entered clinical trials at this time.
Similar efforts have been used to improve the pharmacological properties of LY29002 and derivatives thereof. SF-1126 (compound 5, Figure 2) (Garlich et al., 2008 ) is a water soluble prodrug of LY294002. The compound, which is designed to target specific integrins within the tumor compartment by means of an appended peptide moiety, inhibits all paralogs of PI3K (IC 50 ¼ 0.5-5.7 mM) and other members of the PI3K family, including DNA-PK and mTOR. It blocks the phosphorylation and activation of Akt in cellular settings with IC 50 values in the low micromolar range (for example, IC 50 ¼ 2.4 mM, MM.1S). This prodrug approach appears to enhance the delivery of the active PI3K inhibitor to tumors resulting in significant antitumor activity in xenograft models of brain, neuroblastoma, non-small cell lung, prostate, myeloma, renal and colon carcinoma. In addition to its direct activity on cancer cells, microvessel density analysis of tumor tissue demonstrated that the compound also had significant antiangiogenic activity in vivo. The safety of SF-1126 in humans is currently being tested in phase I trials in which patients are being treated twice per week by i.v. infusion over 1.5 h in treatment cycles of 4 weeks.
In parallel with the synthetic efforts made to overcome the pharmaceutical hurdles encountered with wortmannin and LY294002, high throughput screening and medicinal chemistry activities have been extensively utilized to discover and develop new pan-or paralog selective PI3K modulators. Overall, the new generation of PI3K inhibitors has improved selectivity and druglike properties when compared with the earlier compounds. A number of these compounds are in clinical development and are reviewed below.
NVP-BEZ235 (compound 6, Figure 2 ) is an imidazo [4,5-c] quinoline derivative that inhibits PI3K (IC 50 ¼ 4, 76, 7, 5 and 21 nM against p110a, b, g and d) and mTOR (IC 50 ¼ 21 nM) kinase activity by binding to the ATP-binding cleft of these enzymes (Maira et al., 2008a) . The compound potently inhibits proliferation in a broad panel of tumor cell lines (for example, IC 50 ¼ 10 nM, U87MG cells) by specifically blocking the biological function of PI3K signaling components (for example, IC 50 ¼ 10±1 nM, for inhibition of pSer473-Akt in U87MG cells) and inducing a G1 arrest. The antiproliferative activity of this imidazoquinoline derivative in cellular settings translates well in in vivo models of human cancer (for example, U87MG, PC3M and A549). Thus, compound treatment results in disease stasis or tumor regression when administered orally-25 to 50 mg/kg/day-and enhanced the efficacy when used in in vivo combination studies (for example, docetaxel or temozolomide). Ex vivo pharmacokinetic/pharmacodynamic analyses of tumor tissues upon acute dose or after termination of in vivo efficacy studies showed a timedependent correlation between compound concentration and inhibition of Akt phosphorylation. Additional in vivo experiments have demonstrated marked, compound-mediated alterations in microvessel permeability and significantly reduced tumor interstitial fluid pressure reflecting vascular permeability changes Yuan et al., 2008) . Moreover, early reduction of permeability, as determined by K trans quantification, was found to be a predictive marker for late-stage antitumor activity. This later results suggest that vascular permeability reduction, which can be monitored noninvasively by dynamic contrast-enhanced magnetic resonance imaging might be a useful pharmacodynamic measure in clinical trials and might serve as an early response biomarker predictive of longer-term efficacy. In preclinical in vivo models (Engelman et al., 2008; Serra et al., 2008; Maira et al., 2008a) , NVP-BEZ235 was well tolerated at the efficacious doses when compared with vehicle-treated animals, with no significant difference seen in the body weight. Unlike other modulators of the PI3K/Akt pathway, no statistically significant changes in blood glucose levels were observed in the animals treated with NVP-BEZ235 after in vivo efficacy experiments in mice or rats. Moreover, no effect on insulin or glucose levels was reported for NVP-BEZ235 at efficacious doses at the end of a 13-week rat tolerability study (Marrer et al., 2008) . These preclinical data demonstrate the feasibility of effectively blocking the PI3K/Akt pathway in vivo with manageable effects on glucose regulation. Phase I trials with NVP-BEZ235 inhibitor were initiated in patients with solid tumors at the end of 2006. Patients are enrolled in successive cohorts receiving the compound orally once per day for cycles of 28 days.
XL147 and XL765 (structures not disclosed) are also low-molecular mass PI3K inhibitors in phase I clinical trials. XL-147 is active against class I PI3Ks (IC 50 ¼ 39, 383, 23, 36 nM for p110a, b, g and d, respectively) without inhibiting the kinase activity of Vps34 (IC 50 ¼ 6975 nM), DNA-PK or mTOR (IC 50 >15 000 nM; Foster, 2007; Shapiro et al., 2007) . The compound inhibits PI3K signaling in cultured tumor cells (IC 50 ¼ 0.40-1 mM, pThr308Akt) and blocks vascular endothelial growth factor-induced tubule formation in cellular setting (IC 50 ¼ 529 nM, HMVEC-L). Oral dosing slows tumor growth or induces shrinkage in preclinical models of breast, lung, ovarian, prostate and glioma tumors. Increased tumor growth inhibition over the corresponding single agents was obtained by combining this PI3K inhibitor with cytotoxic or targeted anticancer agents (for example, carboplatin, paclitaxel or erlotinib). XL-765 has a similar activity toward class I PI3K (IC 50 ¼ 39, 113, 9 and 43 nM for p110a, b, g and d, respectively) as XL-147, but, in addition, also inhibits DNA-PK (IC 50 ¼ 150 nM) and mTOR (IC 50 ¼ 157 nM; Laird, 2007; Patnaik et al., 2007) . As in the case of XL-147, tumor growth is delayed or arrested in in vivo efficacy experiments using suitable xenograft tumor models. Interim analyses of ongoing phase I studies with these compounds have shown interpatient variability with terminal half-life values that ranged from 2.5 and 8 days for XL147 and 2-15 h for XL765. Preliminary signs of exposure-dependent pharmacodynamic modulation (changes in plasma insulin levels) were observed at 30/60 mg for XL147 and 15/30 mg b.i.d. for XL765. Analyses of other surrogate tissues, including peripheral blood mononuclear cell lysates and hair follicles, for target modulation are also under investigation.
Imidazopyrimidines and pyridofuropyrimidines with class I PI3K activity have been disclosed in several publications. For example, PI103 (compound 7; Figure 2 ) is a pan-PI3K inhibitor with enzymatic IC 50 values in the 2 nM (PI3Ka) to 15 nM range (PI3Kg) (Fan et al., 2007; Raynaud et al., 2007) . Despite its rapid in vivo metabolism, the compound, which readily distributes to tumor tissue, delays the growth of different subcutaneous human cancer xenografts. Recently, it was shown that PI103 as with other pan-PI3K modulators also inhibits both complexes of mTOR: the rapamycin-sensitive mTORC1 (IC 50 ¼ 0.02 mM) and the rapamycin-insensitive mTORC2 (IC 50 ¼ 0.083 mM). The mTOR biochemical activity was further confirmed in cells, where the compound blocks downstream markers of mTOR signaling (for example, phosphorylation of p70 S6 kinase IC 50 o0.1 mM). PI103 has shown a significant antitumor activity in human glioma xenografts with a significant therapeutic window. Structural modifications of PI103 and derivatives thereof resulted in the identification of GDC-0941 (compound 8; Figure 2 ). This ATP-competitive inhibitor is active against class I PI3K with the following activity profile: IC 50 ¼ 3, 33, 3 and 75 nM for p110a, p110b, p110d and p110g, respectively. In biochemical assays, GDC-0941 demonstrates selectivity over PKs and phosphoinositol 3-kinase related kinase (PIKK) family members (for example, IC 50 ¼ 1.2 and 0.6 mM for DNA-PK and mTOR, respectively). It inhibits p-Akt-Ser473 (IC 50 ¼ 28 nM, MDA-MB-361 in a dose-dependent manner and causes a cell-cycle G1 arrest. Interestingly, GDC-0941 induces apoptosis in a subset of human tumor cell lines, more frequently in cells bearing p110a mutants. Significant in vivo antitumor activity has been observed when administered orally (75-100 mg/kg q.d.) either as a single agent or in combination with other anticancer drugs (for example, taxotere and PD0325901) in athymic mice bearing human tumor xenografts (for example, U87MG, PC3M and MDA.MB.361).
The identification and optimization of the preceding PI3K modulators has certainly benefited by having early access to structural information. The resolution of the X-ray structure for the p110 subunit of PI3Kg (Walker et al., 2000 (Walker et al., , 2001 , and more recently of the human p110a/p85a complex has been fundamental in providing a molecular map of the ATPbinding cleft of this special family of kinases providing the basis for structure-based design approaches. The sequence identity between p110a and p110g is approximately 35% and cross-comparison between the kinase domains of these enzymes shows a root mean square deviation of 1.8 Å between 288 out of 337 aligned Ca atoms. These subtle, but significant conformational shifts, together with a limited number of differences in some of the amino acids that form the ATP-binding cleft of these lipid kinases (for example, aHis885/bGlu858, aGln859/bAsp862, aSer773/bAsp780 and aAla775/ bLys782) may provide the basis for the identification of inhibitors with some level of selectivity for the distinct p110 enzymes. For example, it has been recently shown that modulating and fine-tuning the interactions of the modified molecular template with key amino acids in the ATP-binding pocket can provide paralog-selective PI3K inhibitors for cancer treatment (Redaelli et al., 2003; Knight et al., 2004) . To this end, selectivity trends among compound classes that target PI3K members have been identified by extensive biochemical profiling against all the members of this lipid kinase family (Knight et al., 2006) . According to these results, inhibitors of p110b often tend to inhibit p110d, whereas inhibitors of p110a seem to preferentially inhibit p110g. Interestingly, and in spite of a clear sequence homology in the kinase domain, PIK-75 (compound 9, Figure 2 ), TGX-221 (compound 10, Figure 2 ), AS-605240 (compound 11, Figure 2 ) and IC87114 (compound 12, Figure 2 ) are representative examples of p110a, p110b, p110g and p110d modulators, respectively, that have some level of selectivity against the other p110 paralogs. The in vivo exploration-efficacy and tolerability studies-of compounds with different selectivity profiles is likely to provide important insights into the optimal kinase activity profile to exploit for drug discovery . However, as with any other drug discovery project, the ultimate proof of the 'most desirable lipid kinase activity profile' will come from clinical trials.
Although major advances have been made in the identification of paralog-selective p110 inhibitors, it remains to be seen whether p110a mutation-specific inhibitors for cancer therapeutics can be identified. The number of these mutations and the fact that they are significantly removed from the ATP-binding cleft represents a higher medicinal chemistry hurdle, but it cannot be rule out that alternative inhibitory approaches (for example, allosteric kinase inhibitors or antagonists of protein-protein interactions) may provide the desirable activity and selectivity profile. Additional structural data that could provide detailed information on the mechanisms by which the most common PIK3CA oncogenic mutations affect p110a catalytic activity and its physical contact with the p85a regulatory domain or other interacting proteins will be fundamental to identify p110a mutation-specific modulators.
Inhibitors of the Ser/Thr kinase activity of PDK1
The 3-phosphoinositide-dependent protein kinase-1 (PDK1) is a 556-amino-acid enzyme composed of three well-differentiated motifs: an N-terminal domain, a constitutively activated serine/threonine kinase domain, and a plecstrin homology (PH) domain at its C-terminus (Alessi et al., 1997; Stephens et al., 1998) . Unlike PI3K and Akt, only a single PDK1 isoform has been reported in humans. The attractiveness of PDK1 as a potential anticancer target is linked to its ability to phosphorylate and activate a diverse set of AGC kinase members (named after family members: PKs A, G and C), in particular the three Akt isoforms (PKBa/Akt1, PKBb/ Akt2 and PKBg/Akt3) (Mora et al., 2004) . Full activation of Akt requires phosphorylation at two sites, one within the activation loop (for example, Thr-308 for Akt1), and one within the C-terminus (for example, Ser-473 for Akt1). Phosphorylation of the critical and conserved threonine residue in the activation loop (also called the T-loop) of the three Akt isoforms is carried out by PDK1 at the plasma membrane (Alessi et al., 1996; Stokoe et al., 1997) . In addition to Akt, other members of the AGC kinase subfamily including p70 ribosomal S6 kinase (S6K1), serum and glucocorticoidregulated PK and PKC are phosphorylated and activated by PDK1 (Casamayor et al., 1999) . The established role of PDK1 in the activation of the above proteins and downstream effectors points to its important role in human cancer biology. Finally, PDK1 hypomorphic mice expressing B10% of the normal level of PDK1 display no obvious deleterious phenotypethey are 40-50% smaller than control animals- (Lawlor et al., 2002) , and when crossed to PTEN heterozygote mice abrogate the formation of PTEN deficient tumors. These latter data suggest the possibility that a selective PDK1 kinase inhibitor might provide effective anticancer activity with an acceptable therapeutic index.
One of the most potent, but nonselective PDK1 kinase inhibitor reported to date is UCN-01 (compound 13; Figure 3 ; IC 50 ¼ 6-33 nM) . This staurosporine-based compound, isolated from the culture broth of Streptomyces sp, was originally developed as an inhibitor of calcium-dependent PKC. UCN-01 inhibits a broad array of PKs, including other members of the AGC subfamily of enzymes (for example, IC 50 ¼ 491 nM for Akt) (Komander et al., 2003) . In Drug discovery approaches targeting the PI3K pathway C Garcia-Echeverria and WR Sellers addition to the activity reported in biochemical assays, UCN-01-mediated inhibition of PDK1 has also been observed in in vivo murine and human tumor xenografts . In addition to UCN-01, other staurosporine or maleimide derivatives (for example, compounds 14 and 15; Figure 3 ) have been described as PDK1 modulators (Hill et al., 2001; Fujita and Tsuruo 2003; Komander et al., 2003) .
UCN-01 has been tested in advanced cancer patients in phase I/II clinical trials, both as single agent and in combination with conventional chemotherapeutic drugs (for example, carboplatin, fludarabine or topotecan); however, significant antitumor activities have not yet been reported (Welch et al., 2007) . In addition to pulmonary toxicity, nausea/vomiting, lactic acidosis and transaminitis, UCN-01 induced insulin resistance in the clinic. Owing to the relatively poor selectivity of UCN-01, it is unclear which inhibited kinase(s) is/are involved in this latter side effect, although as shown recently in rat adipose cells, the observed insulin resistance may be owing to the inhibition of Akt phosphorylation and subsequent blockade of insulin-dependent GLUT4 translocation to the plasma membrane (Kondapaka et al., 2004) . If UCN-01-mediated insulin resistance results from PDK1 inhibition, then, contrary to what was observed in the PDK1 hypomorphic mice (vide supra), insulin resistance may represent an important hurdle in the development of PDK1 inhibitors.
A class of aminopyrimidine derivates has also been reported to inhibit PDK1 kinase activity. A representative example of this compound class is BX-320 (compound 16, Figure 3) , an ATP-competitive PDK1 inhibitor (IC 50 ¼ 39 nM) that displays good selectivity over AGC family members (for example, 35-and 146-fold for PKA and PKC, respectively) and other PKs (Feldman et al., 2005) . BX-320 blocks the growth in soft agar of a wide range of tumor cell lines (IC 50 ¼ 0.093-1.32 mM), including PTEN-negative tumor cell lines such as U87MG and PC3M. The compound is also efficacious in a metastasis mouse model-LOX melanoma tumors-when administered orally at 200 mg/kg b.i.d. The resolution of the X-ray structure of the kinase domain of PDK1 with BX-320 revealed a classical two H-bond interactions between the hinge region-the amino-acid backbone of Ala-162-of the enzyme and two of the aminopyrimidine nitrogens of the inhibitor. In this context, the mode of binding of BX-320 is similar to the one reported for aminopyridines in complex with cyclin-dependent kinase 2/cyclin A (Sayle et al., 2003) . The BX series of molecules has not yet entered into the clinical trials at the time of this review.
More recently, the identification and initial medicinal chemistry optimization of an indoline-based series of PDK1 modulators has been reported (Islam et al., 2007a, b) . Using a homology model of the initial indolinone hit bound to PDK1, BX-517 (compound 17, Figure 3 ) was identified as a potent PDK1 inhibitor (IC 50 ¼ 6 nM) with significant selectivity over PKA (IC 50 ¼ 1600 nM; Islam et al., 2007b) . Although not fully understood, the observed selectivity over PKA was rationalized on the basis of negative, steric interactions between the urea moiety of the compound and the side chain of the gatekeeper residue, methionine, of PKA. In the case of PDK1, the gatekeeper is leucine and its shorter side chain may provide room to accommodate the urea group. The binding of the compound was confirmed by the solving of the X-ray structure with PDK1. Additional medicinal chemistry activities provided PDK1 inhibitors with improved pharmacological properties (Islam et al., 2007a) .
The elucidation of the three-dimensional cocrystal structures of PKA, Akt and PDK1 bound to ATP, ATP analogs or kinase inhibitors (Biondi et al., 2000; Yang et al., 2002a; Komander et al., 2004) may provide initial insights into how PDK1 kinase selectivity might be achieved with ATP-competitive inhibitors. We can expect that these structure-based design efforts combined with new screening methods (for example, inverse in silico screening; Zahler et al., 2007) may provide the basis for the identification and development of a new generation of PDK1 modulators with the desirable activity/selectivity profile and pharmacological properties.
Inhibitory activity against PDK1 has also been reported for compounds originally designed to antagonize a different therapeutic target. For example, it has been found that celecoxib (compound 18, Figure 3 ), which is a cyclooxygenase-2 inhibitor, can block the activation of Akt (Hsu et al., 2000) in a variety of cancer cells by inhibiting PDK1 enzymatic activity (Arico et al., 2002) . In an immunoprecipitation assay, the compound inhibits the kinase activity of PDK1 in a dose-dependent manner with an IC 50 value of 3.5 mM. However, weaker inhibitory activity (IC 50 ¼ 30 mM) has been obtained when celecoxib was tested in another cell-free assay using the recombinant PDK1 protein. Interestingly, celecoxib inhibits PDK1 by competing with ATP for binding, and on the basis of this result and using a structure-based design optimization strategy, celecoxib derivatives (for example, OSU-03013, compound 19; Figure 3 ) with slightly improved antiproliferative activity (IC 50 ¼ 3 mM) were identified (Zhu et al., 2004) . Celecoxib itself is currently being investigated in phase II/III clinical studies as a single agent or in combination therapy.
Inhibitors of the Ser/Thr kinase activity of Akt
Akt (also known as PKB) is a serine/threonine kinase belonging to the AGC PK subfamily. Three mammalian isoforms-Akt1, Akt2 and Akt2-have been identified and are broadly expressed although isoform-specific patterns of expression exists in some tissues. The three enzymes have a similar organizational structure: an Nterminal PH domain, a central serine/threonine catalytic domain and a short regulatory region at the C-terminal end containing the so called hydrophobic motif (Jones et al., 1991a, b; Yang et al., 2002b) .
Akt catalyzes the phosphorylation of serine/threonine residues at consensus phosphorylation sites-R-X-R-X-X-S/T-in molecular targets, including proteins with key roles in the regulation of cell growth and survival. As shown in Figure 1 , Akt is a key downstream effector of PI3K. Following the growth factor stimulation of PI3K, Akt is recruited at the plasma membrane, an event accomplished by physical or direct interaction between its PH domain and the generated PtdIns (3,4,5)P 3 molecules (see previous section). Colocalization of PDK1 at the plasma membrane allows the phosphorylation of Thr308, located in the activation loop, by this enzyme, which is necessary and sufficient for Akt activation (Alessi et al., 1996; Bellacosa et al., 1998) . However, maximal enzymatic activation requires phosphorylation of Ser473 located in the C-terminal hydrophobic motif. The molecular identity/ies of the kinase/s, previously referred to as PDK2, required for the phosphorylation of Ser473 has/have been controversial (Feng et al., 2004) , but compelling data point to the mTOR/rictor complex as the key enzyme (Sarbassov et al., 2005) . More recently, DNA-PK was also found to phosphorylate S473 under conditions of DNA damage (Feng et al., 2004; Bozulic et al., 2008) .
Akt isoforms are overexpressed in a variety of human tumors, and, at the genomic level, are amplified in gastric adenocarcinomas (Akt1), ovarian (Akt2), pancreatic (Akt2) and breast (Akt2) cancers (Hill and Hemmings, 2002; Mitsiades et al., 2004) . In addition, many tumor cells display elevated levels of PI3K enzymatic products as a result of deletion/mutations of PTEN, activation of Ras or expression of autocrine growth factors (Maira et al., 2008b) . The biological consequences of uncontrolled Akt activation in tumor cells are critical for inducing, among other effects, a survival signal that allows them to withstand apoptotic stimuli. Thus, Akt protects tumor cells from death by phosphorylating and inactivating components of the intrinsic apoptosis pathway (Downward, 2006) . Nonselective Akt inhibitors have been extensively used as tool compounds to elucidate the role of this kinase in the biology of human cancers. Akt isoforms are potently inhibited by promiscuous kinase inhibitors like staurosporine (compound 20, Figure 4 ; IC 50 ¼ 48-11 nM for Akt1) and derivatives thereof (for example, compound 21, Figure 4) (Kumar et al., 2001; Li and Zhu, 2002) . Similarly, Ro-31-8220 (compound 22, Figure 4 ) is a potent, but nonselective pan-Akt inhibitor, with primary activity against PKC (IC 50 ¼ 10 nM) (Davis et al., 1992) and more modest activity against Akt1 (IC 50 ¼ 240 nM).
Exploiting the X-ray crystal structure of (À)-balanol, which is a potent inhibitor of AGC-kinases, in complex with PKA, medicinal chemistry efforts were directed to impart Akt selectivity and improve its pharmaceutical properties (Gassel et al., 2003; Breitenlechner et al., 2004 Breitenlechner et al., , 2005 . Starting with compound 23 (Figure 4 ) as a lead compound (IC 50 ¼ 5 nM for Akt1 and PKA), a new series of potent Akt inhibitors (for example, compound 24, Figure 4 ; IC 50 ¼ 20 nM for Akt versus IC 50 ¼ 1900 nM for PKA) were obtained by exploiting a binding site in Akt that is narrower in PKA. The X-ray structure of compound 24 bound to PKA shows that the piperidine moiety of the inhibitor adopts an energetically unfavorable envelop conformation to avoid a steric clash with the side chain of phenylalanine-187; these negative interactions do not occur in the modeled complex of the inhibitor bound to Akt; in this protein, the amino acid at position 187 is leucine and not phenylalanine. The activity of these azepane derivatives in cellular settings or in vivo models has not been reported yet.
Promising Akt inhibitors have also been obtained from indazole-pyridine-based derivatives (Luo et al., 2005) . Exemplified by A-443654 (compound 25 , Figure 4 ; Ki ¼ 160 pM for Akt1), these compounds are reversible, ATP competitive inhibitors, which decrease the phosphorylation of Akt downstream targets in cells (for example, GSK3a/b, FOXO3, TSC2 and mTOR) and in vivo in a dose-dependent manner. Interestingly, these biological effects appear to induce Akt Ser-473 phosphorylation in human cancer cell lines, including PTEN-and TSC2-deficient cell lines (Han et al., 2007) . Although several possibilities were considered (for example, a conformational change in the structure of the compound-bound Akt that prevents Ser-473 dephosphorylation or changes in Akt relocalization), further studies will be required to delineate the mechanism(s) involved in this interesting observation. A-443654 shows some level of selectivity against other members of the AGC family: PKA, 40-fold; PKCg, 150-fold; PKCd, 200 and PDK1, >120 000-fold (Luo et al., 2005) . A structural comparison of A-443654 bound to Akt and PKA demonstrated that the compound adopts a binding conformation in Akt that differs from that with PKA (Davies et al., 2007) . In particular, the reported differences in potency of A-443654 for Akt compared with PKA seem to arise as a result of one of the three key residue differences between the ATPbinding clefts: namely the presence of methione-282 in place of leucine at the base of the Akt cleft. This LeuMet substitution allows the inhibitor to adopt a conformation where it can form increased lipophilic contacts with the enzyme. Moreover, the folded conformation adopted by the compound leads to the energetically favorable burial of approximately 50 Å 2 of surface area within the inhibitor itself. Overall, the preceding results nicely show that even when there is a high sequence identity in the ATP-binding pockets of PKs, subtle amino-acid differences can be exploited to achieve selectivity for the intended target.
In animal experiments, the compound showed antitumor activity as a single agent and in combination regimens in a number of tumor xenografts, but the dosing period was limited owing to malaise and weight loss (Shi et al., 2005) . Although further studies with other chemotypes will be required to assess the generality of these in vivo findings, the side effects observed in animal models raise concerns that the therapeutic application of Akt inhibitors will be limited by mechanism-based metabolic toxicities. Recently, compounds with improved potency, selectivity and cardiovascular safety as compared with A-443654, and derivatives thereof, have been reported (Zhu et al., 2004) . A representative example of this series is compound 26 (Figure 4 ) (IC 50 ¼ 0.6 nM, Akt1), which is orally bioavailable in mice (F ¼ 25%) and did not cause hypotension when administered orally in conscious mice up to 150 mg/kg. GSK690693 (compound 27, Figure 4 ) is an ATPcompetitive, pan-Akt kinase inhibitor (for example, IC 50 ¼ 2 nM for Akt1) that recently entered phase I clinical trials (Rhodes et al., 2008) . This aminofurazan derivative is also active (IC 50 o80 nM) against members of the AGC, CAMK and group II PAK kinase families that can contribute to its reported preclinical, antitumor activity. Acute intraperitoneal treatment of severe combined immunodeficient mice bearing BT474 tumors with GSK690693 (20 mg/kg) resulted in acute hyperglycemia with blood glucose levels returning to baseline as the circulating drug concentration decreases. A rapid elevation of plasma insulin levels was also observed, reaching an 880-fold increase in relation to the baseline level at 4 h postdosing. In spite of these observations, the compound was well tolerated with once daily intraperitoneal administration and showed significant antitumor activity in human cancer xenografts (for example, SKOV-3, LNCap, BT474 and HCC-1954) . The first phase I study in humans to investigate the safety, tolerability, PK and pharmacodynamics of this Akt inhibitor given weekly or twice weekly as an i.v. infusion over 1-4 h is ongoing.
If the identification of potent and selective Akt kinase inhibitors has proven difficult, the design of Akt isoform selective modulators represents a higher medicinal chemistry hurdle. The kinase domain of Akt1 has a sequence identity of 90 and 87% with Akt2 and Akt3, Drug discovery approaches targeting the PI3K pathway C Garcia-Echeverria and WR Sellers respectively. Notably, the amino acids that line the ATP-binding cleft of Akt1 are strictly conserved in Akt2, and only one amino acid is different in Akt2 (alanine in Akt1/2 versus valine in Akt3). A detailed molecular map of the ATP-binding pocket of these kinases has been obtained recently by solving the X-ray crystal structure of DPH-Akt2 with adenyl-imidodiphosphate tetralithium salt and a GSK3b-derived peptide (Yang et al., 2002a, b) , but the structure-based design of ATP-competitive Akt isoform selective inhibitors will probably require access to the structures of the full Akt isoforms. Amino acids away from the ATP-binding pocket or the interaction of the kinase domain with other parts of the protein may alter the size and shape of the ATP-binding cleft and hence the binding affinity and selectivity of an ATP-competitive modulator.
Clearly, other pockets besides the ATP-binding cleft can be exploited for the identification and development of Akt kinase modulators. It is notable that allosteric inhibitors of Akt containing the 2,3-diphenylquinoxaline or 5,6-diphenyl-pyrazin-2(1H)-one scaffolds have been described Lindsley et al., 2005; Zhao et al., 2005) . Here, a high throughput homogenous time-resolved fluorescence kinase assay was used to screen around 270 000 compounds for their ability to inhibit Akt enzymatic activity. The identified compound exhibited a linear mixed-type inhibition against ATP and peptide substrate, showed isozyme selectivity, and were only active against the full-length protein (for example, compound 28, Figure 4 ; IC 50 ¼ 2.7 mM for Akt1 versus IC 50 >250 mM for DPH-Akt1). Although the mechanism of inhibition by these allosteric kinase inhibitors has not been fully elucidated and there are no structural data yet, it seems that these molecules may bind outside the ATP-binding pocket, interacting with the PH domain and/or hinge region likely promoting the formation of an inactive conformation. It is important to note that these allosteric inhibitors are slightly less potent than the classical ATP-competitive inhibitors in blocking the kinase activity of a recently reported Akt1 mutant found in breast cancer samples. The mutated protein contains a lysine amino acid instead of glutamic acid at position 17 in the lipidbinding pocket of Akt1 (Carpten et al., 2007) . This single amino-acid mutation leads to constitutive association of Akt1 with the plasma membrane, constitutive activation of the pathway and induces leukemia in mice. In spite of its relatively low frequency, the sensitivity of this mutant to the currently reported Akt modulators, including the allosteric inhibitors reported in the preceding paragraphs, may serve as a clinically relevant predictive marker for directing Akt drug development.
Several follow-up papers have illustrated medicinal chemistry efforts directed to improving the potency and drug-like properties of this compound class (Hartnett et al., 2008; Zhao et al., 2008) . The optimized inhibitor from the disclosed series (compound 29, Figure 4 ) inhibits Akt1 and Akt2 with IC 50 values of 126 and 22 nM, respectively, has a significant selectivity profile against some AGC PKs (IC 50 >10 mM for PKA and PKCa) and a desired pharmacological profile in dogs.
Allosteric inhibition of Akt has also been reported for lactoquinomycin (compound 29, Figure 4) (Toral-Barza et al., 2007) , a natural product isolated from the fermentation broth of a microbial strain Streptomycin sp. LL-AF101. This pyranonathpthoquinone derivative, which was identified by screening a natural product collection, inhibits the kinase activity of Akt1 with an IC 50 value of 0.149 mM and shows significant selectivity over a panel of 45 PKs. Elucidation of its mechanism of action confirmed the formation of a covalent, irreversible bond with the Akt, and mutational analysis highlighted the T-loop cysteine residues-Cys-296 and Cys-310-as critical for kinase inhibition. These two cysteines surround the critical activating Thr-308 amino acid in the catalytic site. In cellular settings, the compound blocks the phosphorylation and activation of Akt and downstream effectors at concentrations consistent with its Akt inhibitory activity. Although this mechanism of Akt inhibition represents an interesting and intriguing approach that might also be applicable to other T-loop cysteine-containing kinases, lactoquinomycin cannot be developed as a drug, among other factors, owing to its nonspecific redox-related cytotoxicity that limits its pharmacological properties and therapeutic window. It remains to be seen whether the structural features of lactoquinomycin responsible for its allosteric, covalent Akt kinase inhibition can be incorporated in other chemical analogs.
Other therapeutic modes to block the PI3K/Akt pathway In addition to directly targeting the kinase components of the PI3K/Akt pathway, alternative therapeutic modes have been pursued to control aberrant pathway activity. Phosphatidylinositol analogs, inositol polyphosphates, phospholipids and hsp90 inhibitors have been used for pathway interruption. Phospholipids and hsp90 inhibitors are reviewed below.
Phospholipids-antagonists of PH domains
Phospholipid-containing molecules have been used in recent years to modulate membrane function and signaling targets that use naturally occurring lipid moieties as substrates or cofactors. Perifosine (NSC 639966/D-21266 compound 31, Figure 5 ) appears to block the activation and phosphorylation of Akt in cellular settings (Kondapaka et al., 2003; Ruiter et al., 2003) . Perifosine is an alkylphosphocholine structurally related to miltefosine, but has an improved tolerability profile with regard to the dose-limiting gastrointestinal side effects reported for the latter. Although the mechanism of action of perifosine is not fully understood, one hypothesis is that, following insertion into the cellular membrane, perifosine interferes with Akt membrane localization by inhibiting the association of its PH domain with PtIns(3,4,5)P 3 . In keeping with this notion, perifosine blocks Akt plasma membrane localization (Engel et al., 2000) as assessed by immunofluorescence imaging (Kondapaka et al., 2003) . Perifosine has marked cytotoxic effects on human tumor cell lines, in particular larynx carcinoma, breast cancer, small cell lung cancer, prostate cancer and colon carcinoma. Of special interest is the synergistic antiproliferative effect observed when perifosine was used in combination with UCN-01 in cell culture assays with PC3 and A459 tumor cells (Dasmahapatra et al., 2004) , with the antiepidermal growth factor receptor antibody, cetuximab, in PTENdeficient cancer cells (Li et al., 2006) and with the hsp90 inhibitor 17-DMAG (see next section) in multiple myeloma cells (Huston et al., 2008) . Blocking simultaneously distinct components of the PI3K/Akt pathway seems to enhance the inhibition of phosphorylation of Akt along with activation of the apoptotic pathway. Recently, it has been shown a statistically significant correlation between the antitumor efficacy of perifosine and quantified downregulation of p-Akt and p-S6 (Hennessy et al., 2007) . Moreover, results obtained from a study of perifosine in MT-1 human breast xenograft suggests that immunomodulation may partly contribute to the anticancer activity of this compound (Safa et al., 1998) . Despite these data, the specific antitumor mechanisms of perifosine and its relationship to Akt inhibition remain unclear.
From the results of phase I studies, a weekly dose of 600 mg or 250 mg/day was selected for phase II studies (Traiser et al., 1998) . Nausea, vomiting and diarrhea (grade 1-3) were the most common side effects at the weekly and daily schedules. Encouraging evidence of antitumor activity as single agent or in combination with radiation was reported in phase I clinical trials, in particular, in the treatment of non-small cell lung cancer patients. However, no significant clinical activity was observed in phase II studies in previously untreated patients with metastatic melanoma (Ernst et al., 2005) , and in patients with progressive, metastatic androgenindependent prostate cancer (Posadas et al., 2005) . An extensive phase II clinical program is currently under way, including trials in breast, head and neck, kidney, lung, prostate, glioma, leukemia, sarcoma and multiple myeloma.
Inhibitors of the ATPase activity of heat-shock protein 90 Heat-shock proteins are ATP-dependent molecular chaperones involved in the folding, stability, activation and cellular localization of a selected range of substrates, the so-called 'client proteins' (Whitesell and Lindquist, 2005) . The Hsp90 family of chaperones is composed of four isoforms: Hsp90a, Hsp90b, GRP94 and TRAP-1. The 90 KDa chaperone binds to client proteins in the presence of other partner proteins to produce a multiprotein complex that folds the target substrate into its biologically active conformation(s). Drug discovery approaches targeting the PI3K pathway C Garcia-Echeverria and WR Sellers
Binding and release of Hsp90 client proteins are regulated by the activity of the N-terminal ATPase domain, which binds and hydrolyzes ATP to mediate a series of association-dissociation cycles between Hsp90 and its substrate. Heat-shock proteins are likely involved in dealing with the cellular stress associated with a hostile cancer environment, as well as being essential for the proper function/folding of a number of key oncogenic proteins. Many of the proteins that interact with Hsp90 are key players in signal transduction pathways that are essential to mediate and sustain tumor cell growth and survival. For example, functional Hsp90 is required for the correct folding and stability of Akt and PDK1. (Basso et al., 2002; Fujita et al., 2002; Solit et al., 2003) . Given the critical roles played by these and other client proteins in tumor growth and survival, inhibition of hsp90 has emerged as a possible strategy for the treatment of human tumors.
The chaperoning function of Hsp90 can be 'switchedoff' by inhibiting its ATPase activity (Chiosis et al., 2004; Dymock et al., 2004) and indeed, most current Hsp90 inhibitors act by binding to the ATP pocket in the N-terminal domain of the protein. Although other inhibitory mechanism are currently under exploration (for example, interference with cochaperone binding and function in the so-called superchaperone complex or binding to the C-terminal nucleotide binding site), this section is focused on the compounds targeting the Nterminal ATP binding cleft (for a recent review on this topic, see Bishop et al., 2007) .
The initial discovery of the potential use of Hsp90 inhibitors as novel anticancer agents was based on two natural products, geldanamycin (compound 32, Figure 5) and radicicol (also called monorden, compound 33, Figure 5 ). These compounds bind into the ATP binding cleft of the N-terminal domain of Hsp90 preventing the chaperone from cycling between its ADP and ATP-bound conformations (Stebbins et al., 1997; Roe et al., 1999) . Both natural products are highly active in preclinical models (Neckers and Neckers, 2002) , but, owing to their poor solubility and other pharmacological issues, the clinical evaluation of geldanamycin and radicicol has not been pursued. In the case of geldanamycin, extensive medicinal chemistry efforts have been made to replace the 17-methoxy substituent and generate analogs with improved pharmaceutical properties. One of these derivatives, 17-allyamino-17-demethoxygeldanamycin (17-AAG, compound 34, Figure 5 ; Jia et al., 2003) , a first-in-class Hsp90 drug, has provided proof-of-concept for Hsp90 inhibition in patients at tolerated doses-(phase I studies are reviewed in Ramanathan et al., 2007) . More recently, KOS953 (tanespimycin), which contains a proprietary form of 17-AAG in a novel, optimized formulation-polyethoxylated castor oil-achieved clinical proof-of-concept with trastuzumab. This combination was well tolerated and tumor regressions were observed exclusively in patients with human epidermal growth factor receptor 2 (erbB2)-positive metastatic breast cancer (Modi et al., 2007) . Phase II monotherapy and combination trials with 17-AAG are currently being carried out.
More recently, additional geldanamycin analogs with increased chemical/metabolic stability and formulation options have been reported. Included among these are 17-(2-dimethylaminoethyl)amino-17-demethoxygeldanamycin (17-DMAG, KOS1022; alvespimycin; compound 35, Figure 5 ; Tian et al., 2004; Hollingshead et al., 2005) and JPI-504 (compound 36, Figure 5 ; Ge et al., 2008) , each having entered clinical trials.
Alvespimycin is a water-soluble analog (11.2 mg/ml) of 17-AAG that has shown in preclinical models comparable or somewhat better antitumor activity in comparison to 17-AAG. The compound had been in phase I clinical trials for the treatment of hematological malignancies and in phase II clinical studies for the treatment of HER2-positive metastatic breast cancer in combination with trastuzumab. It seems that the clinical development of this compound has been discontinued.
IPI-504 (compound 36, Figure 5 ), which is a hydroquinone hydrochloride derivative of 17-AAG, interconverts with 17-AAG in vitro and in vivo through an oxidation/reduction equilibrium (Ge et al., 2008) . It shows a comparable binding affinity for Hsp90 (EC 50 ¼ 63 nM) and Grp94 (EC 50 ¼ 119 nM) and potently inhibits the growth of tumor cell lines that overexpress Hsp90 client protein Her2 (for example, SKBR3, GI 50 ¼ 22 nM and SKOV3, GI 50 ¼ 52 nM). As for other Hsp90 modulators, it is preferentially retained in tumor tissues relative to plasma, and it is efficacious alone (for example, 100 mg/kg 2xw) and in combination with the 20S proteasome inhibitor bortezomib when administered i.v. to mice bearing the RPMI-8226 multiple myeloma model (Sydor et al., 2006) . On the basis of its significant improvement in water solubility and pharmacological properties in relation to 17-AAG, IPI-504 entered phase I clinical trials and its i.v. formulation is currently in phase I/II clinical trials in non-small cell lung cancer (NSCLC) and imatinibresistant gastrointestinal stromal tumor (GIST) tumors. In the phase I trial in GIST and other sarcomas, five metabolic responses were noted, with one true partial response as determined by response evaluation criteria in solid tumors (RECIST) criteria. Clinical activity (as defined by positron emission tomography (PET) response) has also been reported for IPI504 in advanced nonsmall-cell lung cancer tumors and in gastrointestinal stromal tumors. Interestingly, one patient with a mutation in epidermal growth factor receptor, an oncogenic client protein of Hsp90, and prior history of progression on targeted kinase inhibitors experienced extended stable disease over seven cycles (E27 weeks).
Novel HSP90 inhibitor chemotypes are now emerging based on structure-based design and high throughput screening approaches (Janin, 2005; Bishop et al., 2007) . Representative examples of low-molecular mass Hsp90 inhibitors that have entered clinical trials are described in the following paragraphs.
CNF2024 (originally called BIIB021; compound 37, Figure 5 ) is a synthetic orally available Hsp90 mod-ulator that entered clinical trials in October 2005; however, only minimal information is currently in the public domain (Lundgren et al., 2007) . BIIB021 promotes the degradation of the Hsp90 client protein HER-2 with an EC50 of 32 nM in MCF-7 cells and inhibits tumor growth at tolerated doses in human tumor xenograft models expressing high levels of HER2 (for example, N87) or the androgen receptor (for example, CWR22). CNF2024 is in phase II clinical trials for the treatment of GIST, phase I trials in advanced solid tumors and B-cell chronic lymphocytic leukemia and in phase Ib/II in combination with trastuzimab in patients with advanced breast cancer.
SNX-2112 (structure not disclosed) was identified using a protein affinity-displacement assay in which a purine-based affinity resin is used to trap purine-binding proteins derived from cell lysates. SNX-2112 binds to hsp90a and b with low nanomolar affinity (IC 50 ¼ 30 nM), with moderate selectivity over the other hsp90 family members (IC 50 ¼ 862 and 4275 nM, respectively) (Chandarlapaty et al., 2008) . As in the case of geldanamycin and derivatives thereof, SNX-2112 significantly inhibits the proliferation of tumor cell lines by inducing the degradation of relevant client proteins. SNX-5542 (structure not disclosed), which is a watersoluble prodrug of SNX-2112, can be administered orally to tumor-bearing mice and is rapidly converted to SNX-2112 where it preferentially accumulates in tumor tissues, a feature reported for all the current hsp90 modulators. Antitumor activity as a single agent (50 mg/ kg, orally, Monday to Friday schedule) was reported in BT474 and H1650 xenografts. SNX-2112 has entered phase I clinical trials.
NVP-AUY922 (compound 38, Figure 5 ) is one of the most potent synthetic small molecular mass hsp90 inhibitor yet described (Ki ¼ 9.0 and 8.2 nM for Hsp90a and b, respectively; Brough et al., 2008; Eccles et al., 2008; Stu¨hmer et al., 2008) . This isoxazole derivative inhibits the proliferation of human tumor cell lines with IC 50 values of 2.3-50 nM, and induces marked accumulation in either G 1 or G 1 plus G 2 -M phases in most cell lines (Eccles et al., 2008) . Daily dosing of NVP-AUY922 (50 mg/kg intraperitoneal or i.v.) to mice bearing human tumor xenografts with diverse oncogenic profiles produced statistically significant growth inhibition and/or regression, and significant target inhibition evidenced by the depletion of client proteins and induction of hsp70. Significant antitumor activity was also observed when the compound was administered on a weekly i.v. schedule (Jensen et al., 2008) . NVP-AUY922 has entered phase I clinical trials.
Conclusions
The introduction of modulators of the PI3K/Akt pathway as potential targeted anticancer agents is still in an early stage and, despite the lack of complete specificity against the intended target, several interesting compounds have entered clinical trials. The differences in therapeutic response and toxicity observed with the currently available inhibitors in preclinical models suggest that, besides the potential biological effects owing to the concomitant inhibition of other off-targets and/or the intrinsic pharmacological properties of the compound, blocking the PI3K/Akt pathway at different nodes might yield different antitumor activities and therapeutic windows. Although the likelihood of an inhibitor with no off-target activity owing to the inhibition of homologous protein is low, additional preclinical and clinical studies with better characterized compounds or, if possible, more selective inhibitors will be required to determine where and how to block the PI3K/Akt pathway to provide the desired therapeutic outcome. For example, it is unclear whether the activity reported for some of the PI3K inhibitors now in the clinic for members of the lipid kinase family (for example, Vps34 or DNA-PK; Abraham, 2004; Weterings and Chen, 2007; Yan and Backer, 2007 ) is going to be beneficial or preferable to a highly PI3K-or p110a-selective modulator. These types of preclinical studies and the clinical efficacy and tolerability of modulators of the PI3K/Akt are eagerly awaited.
